Company intelligence / Profile preview

623 Medical

San Diego, California, United States623medical.com ↗

Ownership: Private
Development stage: Commercial

Overview

nüm®, the flagship product of 623 Medical, is a sterile vapocoolant spray clinically proven to reduce pain and anxiety associated with needle procedures. It works instantly without messy creams or loud noises and has been validated for sterility throughout its three-year shelf life. Clinical studies show significant reduction in pain during venipuncture compared to placebo or no treatment.

Therapeutic areas: Psychiatry
Modalities: Device (sterile vapocoolant spray)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

nüm

Commercial

Indications: Injection pain, Vaccination pain, Biopsy pain, Venipuncture pain

Beyond the preview

Go deeper on 623 Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 623 Medical.

Explore the full profile